Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of ConcernBusiness Wire • 09/22/21
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021Business Wire • 09/08/21
Arcturus Therapeutics to Present at Upcoming Investor and Scientific ConferencesBusiness Wire • 09/07/21
Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More24/7 Wall Street • 08/10/21
Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline ProgressBusiness Wire • 08/09/21
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 StudyBusiness Wire • 08/03/21
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to DeclineZacks Investment Research • 08/02/21
Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In VietnamBenzinga • 08/02/21
Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In VietnamBenzinga • 08/02/21
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of ConcernBusiness Wire • 08/02/21
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19Business Wire • 08/02/21
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 07/28/21
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021Business Wire • 07/26/21
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal TherapeuticsPRNewsWire • 06/02/21
Arcturus Therapeutics Holdings' (ARCT) CEO Joseph Payne on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/21